Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

Science 316 (5831): 1574-1576

Copyright © 2007 by the American Association for the Advancement of Science

IMMUNOLOGY:
The Shape of Things to Come

Katherine A. Fitzgerald and Douglas T. Golenbock

Mechanistic understanding of how ligands can fine-tune the immune response may lead to better vaccine adjuvants.


The authors are in the Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01605, USA. E-mail: kate.fitzgerald{at}umassmed.edu; douglas.golenbock{at}umassmed.edu


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Toll-like receptor-4 agonist in post-haemorrhage pneumonia: role of dendritic and natural killer cells.
A. Roquilly, A. Broquet, C. Jacqueline, L. Gautreau, J. P. Segain, P. de Coppet, J. Caillon, F. Altare, R. Josien, and K. Asehnoune (2013)
Eur. Respir. J. 42, 1365-1378
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882